ストックスクリーナーアプリを入手
1.1707
16.32%
0.1607
前日終値:
$1.01
開ける：
$1.12
24時間の取引高:
1.12M
Relative Volume:
2.98
時価総額：
$42.88M
収益：
-
当期純損益:
$-9.16M
株価収益率:
-2.0539
EPS:
-0.57
ネットキャッシュフロー:
$-8.75M
1週間 パフォーマンス:
+39.84%
1か月 パフォーマンス:
+24.70%
6か月 パフォーマンス:
-9.63%
1年 パフォーマンス:
-11.00%
1日の値動き範囲:
$1.05
$1.20
1週間の範囲:
$0.8329
$1.20
52週間の値動き範囲:
$0.7006
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
名前
Renovorx Inc
セクター
電話
408-800-2649
住所
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
RNXT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.17 | 37.02M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.73 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
807.79 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.54 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
797.35 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
169.51 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Renovorx Inc (RNXT) 最新ニュース
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - GlobeNewswire
Will RenovoRx Inc. stock see PE expansionShort Setup & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 - Investing News Network
New study aims to make pancreatic cancer chemo hit tumors, not the whole body - Stock Titan
RenovoRx (NASDAQ:RNXT) Stock Price Down 1% – Here’s Why - Defense World
Will RenovoRx Inc. stock pay special dividends2026 world cup usa national team quarterfinals defensive leaders high defensive line knockout prediction expert opinion - ulpravda.ru
RenovoRx receives Nasdaq notice for bid price noncompliance - MSN
RenovoRx Receives Nasdaq Notice for Bid Price Noncompliance - TipRanks
RenovoRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Aug Opening: How RenovoRx Inc stock responds to policy changesQuarterly Profit Summary & Smart Swing Trading Techniques - moha.gov.vn
Shaun Bagai buys RenovoRx (RNXT) shares worth $4506 By Investing.com - Investing.com Australia
Shaun Bagai buys RenovoRx (RNXT) shares worth $4506 - Investing.com India
Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength - Nasdaq
Is RenovoRx Inc. stock attractive for growth ETFsJuly 2025 Setups & Free Long-Term Investment Growth Plans - Улправда
RenovoRx's Differentiated Targeted Drug Delivery Platform Addresses Hypovascular Cancers - Smartkarma
How RenovoRx Inc. stock performs during Fed tightening cyclesIndex Update & Safe Capital Growth Stock Tips - Улправда
How RenovoRx Inc. stock reacts to inflationary pressuresJuly 2025 Intraday Action & Weekly Setup with ROI Potential - Улправда
How RenovoRx Inc. stock responds to policy changesJuly 2025 Retail & Capital Efficient Trade Techniques - DonanımHaber
CEO Bagai Buys 5,000 ($4.3K) Of RenovoRx Inc [RNXT] - TradingView — Track All Markets
Why RenovoRx Inc. stock could outperform in 2025Trade Risk Report & Short-Term High Return Strategies - DonanımHaber
RenovoRx Earnings Notes - Trefis
Can RenovoRx Inc. stock continue upward trendBuy Signal & Free High Accuracy Swing Entry Alerts - Улправда
RenovoRx Executive Makes a Significant Stock Purchase! - TipRanks
Chmn Agah Buys 12,000 ($10.2K) Of RenovoRx Inc [RNXT] - TradingView — Track All Markets
RenovoRx CMO Ramtin Agah Buys 12,000 Shares - TradingView — Track All Markets
RenovoRx, Inc. (RNXT) CMO-director purchases 12,000 shares at $0.85 - Stock Titan
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 - Investing News Network
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO GI 2026 on Innovative Targeted Therapy for Pancreatic Cancer - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) to Present TIGeR-PaC PK/PD Data at ASCO GI Symposium 2026 - Stock Titan
Transcript : RenovoRx, Inc. Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, Dec-09-2025 through Dec-10-2025 - marketscreener.com
RNXT: Six-month survival benefit and strong early revenue position the company for growth in 2026 - TradingView — Track All Markets
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Investing News Network
Agah Ramtin, RenovoRx chief medical officer, buys $9,600 in RNXT - Investing.com
Is RenovoRx Inc. stock near bottom after declineJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - Newser
What makes RenovoRx Inc. stock attractive to growth funds2025 Momentum Check & Weekly Chart Analysis and Guides - Newser
RenovoRx (RNXT) Stock Analysis Report | Financials & Insights - Benzinga
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - Investing News Network
RenovoRx CEO to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) CEO to detail RenovoCath updates at iAccess Alpha - Stock Titan
RenovoRx files $50M mixed securities shelf - MSN
Big Money Moves: Is RenovoRx Inc. stock attractive for growth ETFsMarket Trend Review & Safe Entry Zone Tips - BỘ NỘI VỤ
RenovoRx CMO Makes Bold Stock Purchase - TipRanks
[Form 4] RenovoRx, Inc. Insider Trading Activity - Stock Titan
RenovoRx CMO Ramtin Agah Acquires 22,000 Shares - TradingView
Cipla Limited (CIPLA) Gets Regulatory ApprovalFinancial Sector Performance & Stay One Step Ahead of Risk Events - earlytimes.in
Is RenovoRx Inc. stock positioned for long term growthRisk Management & Reliable Volume Spike Trade Alerts - newser.com
Is RenovoRx Inc. stock a top pick in earnings seasonWeekly Profit Report & Community Driven Trade Alerts - newser.com
RenovoRx Expands Reach with RenovoCath Approval - MSN
Is RenovoRx Inc. stock dividend yield sustainablePortfolio Growth Summary & Risk Managed Investment Signals - newser.com
Published on: 2025-11-19 17:29:20 - newser.com
Tick level data insight on RenovoRx Inc. volatility2025 Retail Activity & Safe Investment Capital Preservation Plans - newser.com
Renovorx Inc (RNXT) 財務データ
収益
当期純利益
現金流量
EPS
5.77%
大文字化:
|
ボリューム (24 時間):